

# COVID-19 Specific Investigational Treatment Recommendations

- There is no current treatment well supported by evidence for COVID-19 infection.
- All specific therapies are investigational.
- It would be strongly preferred to enrol a patient in a clinical trial, if available, as opposed to empiric treatment with these agents.
- Many of these agents are in short supply and may not be available.
- Several professional bodies in Canada and in Ontario recommend against treatment with specific agents outside of a clinical trial.
- **We recommend** against prophylaxis with hydroxychloroquine, azithromycin, or a combination of these drugs. This is supported by a joint statement of the Ontario Pharmacists Association, Ontario Medical Association, and the Registered Nurses Association of Ontario. It can be found [here](#).

## Outpatient Management

- Supportive care
- No specific antimicrobial therapy recommended
- **We recommend against** treatment with hydroxychloroquine.
- **We recommend against** treatment with combination of hydroxychloroquine and azithromycin.
- **We alert providers to the potential for drug-drug interactions** with hydroxychloroquine and azithromycin.

## Admitted – Confirmed cases

### No oxygen requirement

- Supportive care
- No specific antimicrobial therapy recommended

### Confirmed COVID + Oxygen requirement + Comorbidities<sup>1</sup> or Age above 65

- Supportive care
- Phone consultation to Infectious Diseases Physician
- Consider enrollment in available clinical trials

### Confirmed or Suspected COVID Admitted to Critical Care Unit

- Supportive care
- Consider Ceftriaxone 1 g IV daily for 5 days if suspected bacterial infection
- Consult Infectious Diseases Physician
- Consider enrollment in available clinical trials

1 - Comorbidities defined as: respiratory system or cardiovascular disease, hypertension, diabetes, immunocompromised states (e.g. transplant, HIV).

2 - In-vitro antiviral activity against SARS-CoV-2

3 - See Appendix 1 for further information